Phillip Andrew Dennis sold $5,606 of NBP
Chief Medical Officer at NovaBridge Biosciences. 8,494 shares at an average of $0.66, traded Jun 18, 2026, filed Jun 22, 2026.
Score components
- +15RoleOfficer
- 0Trade size$6k at market
- 0Share of holdings soldSold 5.1% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002089237-26-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 17, 2026 | MOption exercise Ordinary Shares | +23,695 | - | - | 166,435 | Jun 22, 2026 |
| Jun 18, 2026 | SOpen-market sale Ordinary Shares | -8,494 | $0.66 | $5,606 | 157,941 | Jun 22, 2026 |
| Jun 17, 2026 | MOption exercise Restricted Share Unitsderivative | -10,302 | $0.00 | $0 | 82,422 | Jun 22, 2026 |
Related signals
Other insiders at NovaBridge Biosciences and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 8Weak | NovaBridge Biosciences | Phillip Andrew Dennis Chief Medical Officer | $5,828 8,209 shares | -5% | |
| 49Moderate | NovaBridge Biosciences | Sean Wuxiong Cao Chief Bus. Development Officer | $80k 107,978 shares | -29% | |
| 8Weak | NovaBridge Biosciences | Cong Claire Xu EVP, Clinical Development | $2,593 3,282 shares | -1% | |
| 0Weak | NBPsell NovaBridge Biosciences | Cong Claire Xu SVP, Clinical Development | $3,992 4,485 shares | -1% | |
| 0Weak | NBPsell NovaBridge Biosciences | Cong Claire Xu SVP, Clinical Development | $14k 3,494 shares | -1% | |
| 31Weak | NBPsell NovaBridge Biosciences | Sean Wuxiong Cao See Remarks | $43k 21,399 shares | -38% | |
| 50Moderate | NBPbuy NovaBridge Biosciences | Mark Arnold Hagler See Remarks | $577k 230,000 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.